SCHEMBL1711041

SCHEMBL1711041

O=C(O)/C=C/c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.84
ALDH1A1 P00352 2/20 0.68
KMT2A Q03164 2/20 0.68
MEN1 O00255 1/20 0.68
NPC1 O15118 1/20 0.68
LMNA P02545 1/20 0.68
RAB9A P51151 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
HCAR2 Q8TDS4 2/20 0.67
HDAC3 O15379 1/20 0.67
TNKS O95271 1/20 0.67
HDAC4 P56524 1/20 0.67
HDAC1 Q13547 1/20 0.67
HDAC7 Q8WUI4 1/20 0.67
HDAC2 Q92769 1/20 0.67
HDAC10 Q969S8 1/20 0.67
HDAC11 Q96DB2 1/20 0.67
HDAC8 Q9BY41 1/20 0.67
TNKS2 Q9H2K2 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1006525 1.00 SRD5A2 (0.84) SRD5A2ALDH1A1KMT2AMEN1NPC1
Methane SCHEMBL9562938 0.98 SRD5A2 (0.81) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL3221757 0.85 BACE1 (0.67) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL14634502 0.85 KMT2A (0.73) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL5582722 0.85 THRB (0.89) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL3221748 0.85 BACE1 (0.67) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL879459 0.85 THRB (0.89) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL10044819 0.85 THRB (0.66) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL18410067 0.85 SRD5A2 (0.64) SRD5A2ALDH1A1KMT2AMEN1NPC1
SCHEMBL9185943 0.85 GLA (0.69) SRD5A2ALDH1A1KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4553069-A1 ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2025-05-14 EP disclosed
CN-119790041-A Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-04-08 CN disclosed
CN-117402123-A Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-01-16 CN disclosed
CN-112204018-B Acrylic compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2023-08-29 CN disclosed
CN-112204018-A Acrylic acid compounds, preparation method thereof, pharmaceutical composition and application 中国科学院上海药物研究所 2021-01-08 CN disclosed
CN-104845642-B Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, phase difference film and method for producing same, polymer and compound JSR株式会社 2020-11-24 CN disclosed
CN-106010582-B Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, retardation film and method for producing same, polymer, and diamine JSR株式会社 2020-04-07 CN disclosed
CN-110483432-A A kind of acrylic compounds and preparation method thereof, pharmaceutical composition and purposes UNIV FUDAN 2019-11-22 CN disclosed
EP-3112930-A1 LIQUID CRYSTAL DISPLAY DEVICE DIC Corporation (JP) 2017-01-04 EP disclosed
US-20160370626-A1 LIQUID CRYSTAL DISPLAY DEVICE DIC CORPORATION (JP) 2016-12-22 US disclosed
US-20100249078-A1 TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE THE SCRIPS RESEARCH INSTITUTE (US) 2010-09-30 US disclosed
US-6005116-A HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA SANKYO COMPANY, LIMITED (JP) 1999-12-21 US disclosed
EP-0885891-A1 ISOXAZOLE DERIVATIVES SANKYO COMPANY LIMITED (JP) 1998-12-23 EP disclosed
EP-0299457-B1 Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome WARNER LAMBERT CO (US) 1994-09-21 EP disclosed
US-4931459-A ADMINISTERING SUBSTITUTED BENZOTHIOPHENES OR BENZOFURANS WARNER-LAMBERT COMPANY (US) 1990-06-05 US disclosed
US-4910317-A Containing a 5-amidetetrazole substitution in position 2 WARNER-LAMBERT COMPANY (US) 1990-03-20 US disclosed
EP-0299457-A2 Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome WARNER-LAMBERT COMPANY (US) 1989-01-18 EP disclosed
US-3995054-A MITICIDES ZOECON CORPORATION (US) 1976-11-30 US disclosed
US-3975429-A Cyclopropanemethyl esters of cinnamic acid and derivatives thereof ZOECON CORPORATION (US) 1976-08-17 US disclosed
US-3966801-A ANTIINFLAMMATORY AGENTS WILLIAM H. RORER, INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249078-A1 TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, APEH SRD5A2 2567/4885ALDH1A1 1136/4885KMT2A 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.